On August 29, 2025, Foresight Diagnostics, a privately held cancer diagnostics company and CLIA-registered laboratory, announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, Roche) involving Foresight’s patented PhasED-Seq™ technology. The agreement resolves litigation between the parties, with all claims against Foresight, its founders, and Stanford University dismissed with prejudice. Wilson Sonsini Goodrich & Rosati advised Foresight on the settlement and licensing agreement.

Under the agreement, Foresight granted Roche a limited, royalty-bearing, non-exclusive sublicense under certain patents for the use of PhasED-Seq for performing services and commercializing in vitro diagnostic (IVD) kits for Non-Hodgkin’s Lymphoma (NHL). The patents are owned by Stanford University, and Foresight holds the exclusive license for all uses and geographies.

The Wilson Sonsini team included Ian Edvalson, Maya Skubatch, Nguyen Pham, and Rex Watkins.

For more information, please see Foresight Diagnostics’ press release.